Business
Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on
About this update from Ironwood Pharmaceuticals, Inc.
[{"type":"text","content":" BOSTON--(BUSINESS WIRE)--\nIronwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 2:15 p.m. ET at the Encore Boston Harbor.\n\n\nA live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website for 1 year following the conference.\n\n\nAbout Ironwood Pharmaceuticals\n\n\nIronwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years-old. Ironwood is also advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF), as well as several earlier stage assets. Building upon our history of GI innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.\n\n\nFounded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.\n\n\nWe routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on X and on LinkedIn.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240829395243/en/\n\nInvestors:\n\n\nGreg Martini, 617-374-5230\[email protected]\n\n\nMatt Roache, 617-621-8395\[email protected]\n\n\nMedia:\n\n\nBeth Calitri, 978-417-2031\[email protected]\n\n\nSource: Ironwood Pharmaceuticals, Inc.","length":4900,"tagName":"div"}]